Neurocrine Biosciences (NBIX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX)

NBIX 141.80

+0.6%

Dec 31 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (580)	4/11/2000 9:21:00 PM
From: Miljenko Zuanic	Read Replies (1) of 1834

Short update on CRF-R1 program. Thanks to Paul Hawran, NBIX CFO, for update information. Janssen back-up compound is from new library and at least 12 months behind NBIX candidate. NBIX will continue with their own CRF-R1 antagonist program until they are ready for partner. However, their interest is more than small US royalty, based primarily on the program value and their candidate preclinical data. For insomnia candidate, NBI34060, they have broad PII program and they fill very confident that it will be at least equal if not better than current therapy. Here I share their optimism and looking forward for PII results. Also, seams that NBIX didn't hold news on Janssen decision about R121, which was really unexpected. So, NBIX management's wasn't responsible for early news leak (higher volume on day news was released is coming from leak which is generally hard to control) and price decline from upper 40. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next